Xcout IntelRestore Vision competitors & alternatives
The 12 closest competitors and alternatives to Restore Vision among biotechnology companies — ranked by similarity to what Restore Vision actually does, not by market-cap band.
Subscribe to see Restore Vision’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Restore Vision
Restore Vision Inc. is a Japanese startup headquartered in Tokyo that aims to develop visual restoration gene therapies.
Restore Vision at a glance
Restore Vision is a biotechnology company headquartered in Japan. It has raised at least $8.5M across the 2 funding rounds on record, 1 of them with a disclosed amount. Its most recent funding round, Series A, raised $8.5M in April 2026. Xcout tracks 9 named people at Restore Vision, including Yusaku Katada (CEO).
Restore Vision leadership
- Yusaku KatadaCEO
- Hikaru MiyazakiCOO
- Takahiro TadokoroCSO 研究開発本部長
- Teru Miyazaki代表取締役COO
- Hideki Kandorico-founder
- Toshihide Kuriharaco-founder
3 more named people on record for Restore Vision, with roles, board committees and tenure — see the full roster →
Restore Vision funding rounds
At least $8.5M raised across the 2 rounds on record (1 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $8.5M | 8 named | |
| Series A | Undisclosed | 8 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Restore Vision competitors
Ranked by semantic similarity — how close each company is to Restore Vision by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Ray Therapeutics, Inc. is a privately held optogenetic gene therapy company headquartered in Berkeley, California. The company focuses on reimagining vision through innovative genetic treatments and novel therapeutic solutions.
Biotech
Rejuvenate Bio, Inc. is a biotechnology company founded in 2019 and headquartered in San Diego, United States, specializing in innovative gene therapy applications.
Biotech
Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic modulation of specific genetic loci. Modalis also has a collaborative research agreement with JCR Pharmaceuticals Co., Ltd., aimed at assessing gene therapy drug delivery methods for the central nervous system (CNS), particularly for CNS-related disorders. Founded in 2016, the company was initially known as EdiGENE Corporation before changing its name to Modalis Therapeutics Corporation in August 2019. Its operations are based in Tokyo, Japan.
Similar biotechnology company
SparingVision is a genomic and gene therapy medicines company translating pioneering science into vision-saving treatments, with US headquarters located in Boston, Massachusetts.
Similar biotechnology company
Beacon Therapeutics is a clinical-stage biotechnology company dedicated to saving and restoring sight for people living with rare and prevalent ocular diseases. The company works to deliver advanced retinal gene therapies to patients experiencing blindness.
Similar biotechnology company
Coave Therapeutics is a clinical-stage biotechnology company headquartered in Paris, France. The company focuses on developing life-changing gene therapies targeting rare ocular and central nervous system diseases.
Similar biotechnology company
Eyevensys is a biotechnology company developing non-viral gene therapies for ophthalmic diseases. Its platform uses electro-transfection of the eye’s ciliary muscle to enable sustained local production of therapeutic proteins for retinal and other ocular conditions.
Biotech
Adverum Biotechnologies is a clinical-stage biotechnology research company headquartered in Redwood City, California. The company focuses on developing novel gene therapies designed to redefine ocular care and treat severe eye diseases.
Similar biotechnology company
Atsena Therapeutics, Inc. is a clinical-stage gene therapy company headquartered in Durham, North Carolina, established in 2019. The firm focuses on developing novel gene therapies to treat debilitating inherited blinding diseases using proprietary vector delivery technologies. Its scientific pipeline aims to address areas of high unmet medical need in ophthalmology.
Similar biotechnology company
Junten Bio Co. Ltd. is a Japanese pharmaceutical and biotechnology corporation headquartered in Tokyo, specializing in the research and development of cell and regenerative medicine.
Life Science
ReCode Therapeutics is a clinical-stage genetic medicines company headquartered in Menlo Park, California, and Durham, North Carolina. The company leverages proprietary delivery systems to power a new class of disease-modifying genetic therapies.
Similar biotechnology company
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Restore Vision and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Restore Visionand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →